ES2470816B1 - Proteína recombinante y usos en el diagnóstico de la esclerosis múltiple - Google Patents

Proteína recombinante y usos en el diagnóstico de la esclerosis múltiple Download PDF

Info

Publication number
ES2470816B1
ES2470816B1 ES201231815A ES201231815A ES2470816B1 ES 2470816 B1 ES2470816 B1 ES 2470816B1 ES 201231815 A ES201231815 A ES 201231815A ES 201231815 A ES201231815 A ES 201231815A ES 2470816 B1 ES2470816 B1 ES 2470816B1
Authority
ES
Spain
Prior art keywords
diagnosis
multiple sclerosis
recombinant protein
antibodies
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201231815A
Other languages
English (en)
Other versions
ES2470816A1 (es
Inventor
Óscar FERNÁNDEZ FERNÁNDEZ
Begoña OLIVER MARTOS
Teresa ÓRPEZ ZAFRA
José PAVÍA MOLINA
Critobalina MAYORGA MAYORGA
Laura LEYVA FERNÁNDEZ
María Jesús PINTO MEDEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Malaga
Servicio Andaluz de Salud
Instituto Mediterraneo para el Avance de la Biotecnologia y la Investigacion Sanitaria (Fundacion Imabis)
Original Assignee
Universidad de Malaga
Servicio Andaluz de Salud
Instituto Mediterraneo para el Avance de la Biotecnologia y la Investigacion Sanitaria (Fundacion Imabis)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Malaga, Servicio Andaluz de Salud, Instituto Mediterraneo para el Avance de la Biotecnologia y la Investigacion Sanitaria (Fundacion Imabis) filed Critical Universidad de Malaga
Priority to ES201231815A priority Critical patent/ES2470816B1/es
Priority to PCT/ES2013/070812 priority patent/WO2014080063A1/es
Priority to EP13856322.6A priority patent/EP2930183B1/en
Priority to US14/443,814 priority patent/US10393758B2/en
Publication of ES2470816A1 publication Critical patent/ES2470816A1/es
Application granted granted Critical
Publication of ES2470816B1 publication Critical patent/ES2470816B1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7156—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Proteína recombinante y usos en el diagnóstico de la esclerosis múltiple.#Proteína recombinante IFNAR2.3, anticuerpos, composiciones que los comprenden, y usos. Entre sus usos, especialmente, se refiere a un método para el diagnóstico de la esclerosis múltiple, así como al kit de diagnóstico.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23

Claims (1)

  1. imagen1
    imagen2
ES201231815A 2012-11-22 2012-11-22 Proteína recombinante y usos en el diagnóstico de la esclerosis múltiple Active ES2470816B1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES201231815A ES2470816B1 (es) 2012-11-22 2012-11-22 Proteína recombinante y usos en el diagnóstico de la esclerosis múltiple
PCT/ES2013/070812 WO2014080063A1 (es) 2012-11-22 2013-11-22 Proteína recombinante y usos en el diagnóstico de la esclerosis múltiple
EP13856322.6A EP2930183B1 (en) 2012-11-22 2013-11-22 Recombinant protein and uses thereof in the diagnosis of multiple sclerosis
US14/443,814 US10393758B2 (en) 2012-11-22 2013-11-22 Methods for treating or ameliorating multiple sclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201231815A ES2470816B1 (es) 2012-11-22 2012-11-22 Proteína recombinante y usos en el diagnóstico de la esclerosis múltiple

Publications (2)

Publication Number Publication Date
ES2470816A1 ES2470816A1 (es) 2014-06-24
ES2470816B1 true ES2470816B1 (es) 2015-04-01

Family

ID=50775586

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201231815A Active ES2470816B1 (es) 2012-11-22 2012-11-22 Proteína recombinante y usos en el diagnóstico de la esclerosis múltiple

Country Status (4)

Country Link
US (1) US10393758B2 (es)
EP (1) EP2930183B1 (es)
ES (1) ES2470816B1 (es)
WO (1) WO2014080063A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2626002B1 (es) * 2015-12-21 2018-05-10 Servicio Andaluz De Salud Uso de la proteína IFNAR como antiviral
WO2020070363A1 (es) * 2018-10-02 2020-04-09 Servicio Andaluz De Salud Método para predecir o pronosticar la respuesta al tratamiento de la esclerosis múltiple con interferón beta.
EP4191247A1 (en) * 2021-12-02 2023-06-07 ALA Diagnostics, S.L. In vitro method for the diagnosis and/or prognosis of multiple sclerosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821078A (en) * 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
IL107378A (en) 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation
US20040018522A1 (en) * 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis

Also Published As

Publication number Publication date
WO2014080063A1 (es) 2014-05-30
EP2930183A4 (en) 2016-06-08
EP2930183B1 (en) 2020-09-23
US20160011212A1 (en) 2016-01-14
EP2930183A1 (en) 2015-10-14
US10393758B2 (en) 2019-08-27
ES2470816A1 (es) 2014-06-24

Similar Documents

Publication Publication Date Title
CL2014000114A1 (es) Anticuerpo que se une a r-espondina 1 humana (rspo1); polipéptido que comprende un anticuerpo; composición farmacéutica que comprende el anticuerpo; uso para inhibor el crecimiento de un tumor.
ECSP14004976A (es) Anticuerpos anti-il-36r
BR112014008089A2 (pt) método para diagnosticar o mal de alzheimer, uso do método, e, kit para a realização do método
AR107786A1 (es) Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
ES2470816B1 (es) Proteína recombinante y usos en el diagnóstico de la esclerosis múltiple
CL2015001458A1 (es) Composición simbiotica y el uso de la misma.
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
BR112013020369A8 (pt) peptídeos modificados hidrofóbicos para diagnóstico específico do fígado.
AR089060A1 (es) Composiciones para el cuidado bucal
DK3084442T3 (da) Diagnostiske reagenser til forbedret in vivo eller in vitro cellemedieret immunologisk diagnosticering af tuberkulose
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
ES2644989T3 (es) Mecanismo de activación para encendedor
ES2644293T3 (es) Dispositivo de compresión médico
ES2585558T3 (es) Uso de sales de 3-carboxi-N-etil-N,N-dimetilpropan-1-aminio en el tratamiento de una enfermedad cardiovascular
ES2642712T3 (es) Péptidos de foenixina
ES2495266B1 (es) Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
ES2533758B1 (es) Composición que comprende albúmina para su utilización en el tratamiento de cirrosis descompensada
ES2526935B2 (es) Compuestos para el tratamiento de infecciones por Leishmania
ES2433749B1 (es) Biomarcadores de la enfermedad de Chagas
ES2426017B1 (es) Microemulsión que comprende colagenasa y usos
ES2641926T3 (es) Preparado alimenticio
ES2461016B1 (es) Método para el diagnóstico y/o pronóstico de obesidad mórbida
ES2538719B1 (es) Racemasa BsrAb para la racemización de aminoácidos
ES2443542B1 (es) Estañosilicatos laminares, procedimientos de obtención y usos de los mismos
Shata Supervisors: Dr. Samia Mahdi Ahmed

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2470816

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150401